Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Arrowhead Pharmaceuticals to Host R&D Day on RNAi-Based Therapies

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a Research & Development Day to discuss its pipeline of RNAi-based therapies on September 14 in New York City.

Arrowhead Pharmaceuticals to Host R&D Day on RNAi-Based Therapies

Pasadena. CA | Posted on September 1st, 2017

The R&D Day will feature presentations by key opinion leaders (KOLs) Jeffrey Teckman, MD (St. Louis University School of Medicine), Stephen Locarnini, PhD (Victorian Infectious Diseases Reference Laboratory), and Ira Goldberg, MD (NYU Langone Medical Center), who will discuss the current treatment landscape and unmet medical need for patients with alpha-1 liver disease, hepatitis B (HBV), and cardiovascular disease, respectively.

Arrowhead's management team will provide an overview of the Company's new platform technology and its pipeline of RNAi-based therapeutics. Discussion topics will include:

The Targeted RNAi Molecule (TRiM) Platform, which includes delivery targeted to the liver, tumors, and another tissue to be disclosed at the event
ARO-AAT for liver disease associated with alpha-1 antitrypsin deficiency
ARO-HBV for chronic hepatitis B infection
ARO-APOC3 for cardiovascular diseases
Updates on Arrowhead's clinical development timelines
This event is intended for institutional investors, sell-side analysts, investment bankers, and business development professionals only. Please RSVP in advance if you plan to attend, as space is limited. To reserve a seat, email or contact LifeSci Advisors, LLC at

A live and archived webcast of the event, with slides, will be available on Arrowhead's website at

About the KOLs

Jeffrey H. Teckman, MD serves as Director, Division of Gastroenterology and Hepatology, Department of Pediatrics and Professor of Pediatrics, Biochemistry and Molecular Biology at St. Louis University School of Medicine. Dr. Teckman also serves as the Scientific Advisor of The Alpha-1 Project, Inc. and as the Director of Gastroenterology and Hepatology at Cardinal Glennon Children's Medical Center in Saint Louis, Missouri. Dr. Teckman is a consultant to the pharmaceutical industry for projects on drug safety and drug development and is involved in patient advocacy for genetic disease anti-discrimination efforts. He is a volunteer and patient educator for the American Liver Foundation and the Alpha-1 Foundation. He has been involved in research on Alpha-1 Antitrypsin Deficiency and other liver diseases for 25 years. Dr. Teckman's work has been recognized with awards for research, patient care and service, including the Miles and Shirley Fiterman Basic Research Award in Gastroenterology and Best Doctors in America.

Professor Stephen Locarnini, BSc, (Hons), PhD, MBBS, FRC (Path) is the Head of Research & Molecular Development at Victorian Infectious Diseases Reference Laboratory (VIDRL, originally Fairfield Hospital Laboratory). He is also Director of World Health Organization (WHO) Regional Reference Laboratory for Hepatitis B. His current major research interests include viral hepatitis, hepatitis vaccines, and antiviral chemotherapy with an emphasis on the basic virology of the various agents of hepatitis, the molecular pathogenesis of hepatitis, as well as prevention and public health control measures. The treatment of hepatitis B and C infections with antiviral agents represents a major focus. Professor Locarnini is the recipient of numerous awards including the Malaysian Liver Foundation Medal for work on Viral Hepatitis, the Bristol Myers Squibb Freedom to Discover Award and is the 2011 recipient of the European Association for the Study of the Liver (EASL) award for Scientific Recognition. He is author of over 200 peer-reviewed articles, 15 invited editorials and over 70 book chapters and reviews and every year for the past 5 years, has delivered a number of invited and plenary lectures at major international conferences. Professor Locarnini has recently co-founded the NGO, Coalition to Eradicate Viral Hepatitis in Asia-Pacific (CEVHAP).

Ira Goldberg, MD is currently the Chief of the Division of Endocrinology, Diabetes and Metabolism at New York University Langone School of Medicine. Dr. Goldberg has published over 200 articles. These include written numerous book chapters, editorials, and reviews. He is an associate editor of both the Journal of Lipid Research and Journal of Clinical Lipidology. Dr. Goldberg's research has focused on abnormalities of lipoprotein metabolism, macrovascular disease in diabetes, and the role of triglycerides in atherosclerosis. He has received grant support in a number of investigational studies that involve atherogenicity of apolipoprotein B-containing lipoproteins, regulation of plasma triglyceride by lipase enzymes, diabetic macrovascular disease, and lipid uptake and toxicity in the heart. Among Dr. Goldberg's honors is a MERIT Award from the National Heart, Lung, and Blood Institute. He has previously served as chair of the NIH Metabolism and CADO (cellular aspects of diabetes and obesity) study sections.


About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit .

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA

Investors and Media:
LifeSci Advisors, LLC
Matthew P. Duffy

Copyright © Arrowhead Pharmaceuticals, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

GLOBALFOUNDRIES and Soitec Enter Into Long-term Supply Agreement on FD-SOI Wafers: Strategic milestone to help guarantee a secure, high-volume supply of FD-SOI technology September 20th, 2017

GLOBALFOUNDRIES Announces Availability of mmWave and RF/Analog on Leading FDX™ FD-SOI Technology Platform: Technology solution delivers ‘connected intelligence’ to next generation high-volume wireless and IoT applications with lower power and significantly reduced cost September 20th, 2017

GLOBALFOUNDRIES Announces Availability of Embedded MRAM on Leading 22FDX® FD-SOI Platform: Advanced embedded non-volatile memory solution delivers ‘connected intelligence’ by expanding SoC capabilities on the 22nm process node September 20th, 2017

Copper catalyst yields high efficiency CO2-to-fuels conversion: Berkeley Lab scientists discover critical role of nanoparticle transformation September 20th, 2017


Do titanium dioxide particles from orthopedic implants disrupt bone repair? September 16th, 2017

Arrowhead Hosts Investor & Analyst R&D Day to Introduce TRiM(TM) Platform and Lead RNAi-based Drug Candidates September 14th, 2017

Graphene based terahertz absorbers: Printable graphene inks enable ultrafast lasers in the terahertz range September 13th, 2017

Applications for the nanomedTAB are open until September 18th, 2017 September 13th, 2017


GLOBALFOUNDRIES Delivers 8SW RF SOI Technology for Next-Generation Mobile and 5G Applications: Advanced 8SW 300mm SOI technology enables cost-effective, high-performance RF front-end modules for 4G LTE mobile and sub-6GHz 5G applications September 20th, 2017

GLOBALFOUNDRIES Unveils Vision and Roadmap for Next-Generation 5G Applications: Technology platforms are uniquely positioned to enable a new era of ‘connected intelligence’ with the transition to 5G September 20th, 2017

GLOBALFOUNDRIES Delivers Custom 14nm FinFET Technology for IBM Systems: Jointly developed 14HP process is world’s only technology that leverages both FinFET and SOI September 20th, 2017

GLOBALFOUNDRIES Introduces New 12nm FinFET Technology for High-Performance Applications September 20th, 2017


Leti Develops Proof of Concept to Test Wireless Systems in Aircraft: Will Present Results of Joint Project at AeroTech Conference And Exhibition in Fort Worth, Texas, Sept. 26-28 September 20th, 2017

Applications for the nanomedTAB are open until September 18th, 2017 September 13th, 2017

Silk could improve sensitivity, flexibility of wearable body sensors August 20th, 2017

FRITSCH • Milling and Sizing! Innovations at POWTECH 2017 - Hall 2 • Stand 227 August 9th, 2017


Do titanium dioxide particles from orthopedic implants disrupt bone repair? September 16th, 2017

Applications for the nanomedTAB are open until September 18th, 2017 September 13th, 2017

Magnetic cellular 'Legos' for the regenerative medicine of the future September 12th, 2017

How to draw electricity from the bloodstream: A one-dimensional fluidic nanogenerator with a high power-conversion efficiency September 11th, 2017

The latest news from around the world, FREE

  Premium Products
Only the news you want to read!
 Learn More
University Technology Transfer & Patents
 Learn More
Full-service, expert consulting
 Learn More

Nanotechnology Now Featured Books


The Hunger Project